# Pasireotide Treatment for Neuroendocrine Tumor

> **NCT02779257** · PHASE4 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Gastro-enteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Pasireotide
- **DRUG:** Diazoxide

## Key facts

- **NCT ID:** NCT02779257
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Subject passed away prior to enrollment
- **Last updated:** 2022-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779257, "Pasireotide Treatment for Neuroendocrine Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02779257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*